A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

September 12, 2023

Primary Completion Date

June 12, 2025

Study Completion Date

March 31, 2026

Conditions
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)Richter's SyndromeT-cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)Marginal Zone LymphomaMyeloid MalignanciesAcute Myeloid Leukemia (AML)Chronic Myelomonocytic Leukemia (CMML)Myelodysplastic Syndrome (MDS)MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
Interventions
DRUG

PRT2527

PRT2527 will be administered by intravenous infusion once weekly.

DRUG

Zanubrutinib

Zanubrutinib will be provided in capsules for oral administration once or twice daily.

DRUG

Venetoclax

Venetoclax will be provided in tablet for oral administration once daily

Trial Locations (24)

3004

Alfred Health, Melbourne

3084

Austin Health, Heidelberg

3168

Monash Health, Melbourne

6009

Linear Clinical Research Ltd, Perth

6500

Ente Ospedaliero Cantonale (EOC) lstituto Oncologico della Svizzera italiana (IOSl)- Ospedale San Giovanni (ORBV), Bellinzona

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York

20817

American Oncology Partners of Maryland, PA, Bethesda

22903

University of Virginia Comprehensive Cancer Center, Charlottesville

40138

IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola, Bologna

42601

Keimyung_University Dongsan Hospital, Daegu

47014

"lstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST", Meldola

47392

lnje University Busan Paik Hospital, Busan

48121

Ospedale Santa Maria delle Croci - AUSL della Romagna, Ravenna

50937

Universitatsklinikum Koln, Klinik I fur lnnere Medizin, Cologne

59000

Claude Huriez Hospital, Lille

91010

City of Hope, Duarte

92210

Institut Curie, Saint-Cloud

94010

Hopital Henri Mondor, Créteil

02215

Dana-Farber Cancer Institute, Boston

H3T 1E2

Jewish General Hospital, Montreal

69373 Cedex 08

Centre Léon Bérard, Lyon

30-727

Pratia MCM Krakow, Krakow

06351

Samsung Medical Center, Seoul

LS9 7TF

The Leeds Teaching Hospitals NHS Trust, St James University Hospital, Leeds

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

BeiGene

INDUSTRY

lead

Prelude Therapeutics

INDUSTRY

NCT05665530 - A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies | Biotech Hunter | Biotech Hunter